$50.25
2.34% yesterday
Nasdaq, Nov 25, 10:04 pm CET
ISIN
US23282W6057
Symbol
CYTK

Cytokinetics, Incorporated Stock price

$50.25
-1.07 2.09% 1M
+1.95 4.04% 6M
-33.24 39.81% YTD
+18.42 57.87% 1Y
+9.35 22.86% 3Y
+40.75 428.95% 5Y
+45.85 1,042.05% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+1.15 2.34%
ISIN
US23282W6057
Symbol
CYTK
Sector
Industry

Key metrics

Market capitalization $5.93b
Enterprise Value $5.71b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1,772.60
P/S ratio (TTM) P/S ratio 1,841.68
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -58.81%
Revenue (TTM) Revenue $3.22m
EBIT (operating result TTM) EBIT $-524.63m
Free Cash Flow (TTM) Free Cash Flow $-407.05m
Cash position $1.01b
EPS (TTM) EPS $-5.39
P/E forward negative
P/S forward 432.48
EV/Sales forward 416.26
Short interest 20.31%
Show more

Is Cytokinetics, Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Cytokinetics, Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Cytokinetics, Incorporated forecast:

14x Buy
78%
4x Hold
22%

Analyst Opinions

18 Analysts have issued a Cytokinetics, Incorporated forecast:

Buy
78%
Hold
22%

Financial data from Cytokinetics, Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3.22 3.22
59% 59%
100%
- Direct Costs 13 13
33% 33%
419%
-10 -10
337% 337%
-319%
- Selling and Administrative Expenses 184 184
6% 6%
5,702%
- Research and Development Expense 317 317
2% 2%
9,853%
-511 -511
5% 5%
-15,874%
- Depreciation and Amortization 13 13
33% 33%
419%
EBIT (Operating Income) EBIT -525 -525
6% 6%
-16,293%
Net Profit -576 -576
9% 9%
-17,901%

In millions USD.

Don't miss a Thing! We will send you all news about Cytokinetics, Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cytokinetics, Incorporated Stock News

Positive
Reuters
7 days ago
Bayer on Tuesday struck a collaboration deal with U.S. biotech firm Cytokinetics to acquire certain rights in Japan to an experimental heart drug, as the German group strengthens its cardiovascular business with smaller deals.
Neutral
GlobeNewsWire
7 days ago
Approximately €70 Million in Upfront and Near-term Payments to Cytokinetics Up to €490 Million in Commercial Milestone Payments, with Tiered Royalties on Future Sales SOUTH SAN FRANCISCO, Calif. and BERLIN, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Bayer today announced they have entered into a collaboration and license agreement for the exclusive developme...
Neutral
GlobeNewsWire
10 days ago
Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of Life
More Cytokinetics, Incorporated News

Company Profile

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Head office United States
CEO Robert Blum
Employees 423
Founded 1997
Website www.cytokinetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today